Amphotericin B liposome for injection

DRUG2 trials

Sponsors

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Conditions

Bioequivalence

Phase 1

A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy Subjects

CompletedNCT04993222

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Bioequivalence

Start: 2020-06-04End: 2020-11-16Updated: 2021-08-06

Bioequivalence of Amphotericin B Liposome for Injection

CompletedNCT05913921

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Bioequivalence

Start: 2023-06-02End: 2023-09-01Updated: 2023-09-28